Refer to the following for general information and guidance on COVID-19:
- Important Therapeutic Goods Administration (TGA) Medicines Shortage Advice regarding intravenous Tocilizumab (Actemra) in clinical trial settings.
- Clinical Trials Project Reference Group (CTPRG) national guidance: COVID-19 Guidance on clinical trials for institutions, HRECs, researchers and sponsors
- Combined industry guidance: Joint Position Statement from Research & Development Taskforce (RDTF) – Supporting Clinical Trials during the COVID-19 pandemic
- NHMRC COVID-19 impact statement
- Victorian HREC Research Managers COVID-19 statement:
In response to the unprecedented COVID-19 pandemic, Hospital Research Ethics & Governance Offices across Victoria are working to ensure that ethics and governance reviews of COVID-19 related clinical trials and health research projects are encouraged, supported and expedited to meet these challenging times.
We ask for patience, flexibility and creativity from all stakeholders as we work together to accelerate research during this rapidly evolving healthcare emergency.
The Hospital Research Managers Sub-Committee is supported by the Melbourne Academic Centre for Health, Monash Partners and Western Alliance.
Refer to the list of Victorian hospital Research Office for contact details .
Please contact Monash Partners Academic Health Science Centre on 03 8572 2637 for further information regarding Victorian HRECs.
- PICF for Future Unspecified Non-Interventional Coronavirus or Related Research - for collection of health information and samples. Information in the PICF refers to Victorian legislation. If using this PICF under NMA it will be necessary for other jurisdictions to insert specific legislation (if applicable) for health information and samples.